Celldex Therapeutics Inc represents a commitment to advancing breakthrough immunotherapies to treat cancer and other devastating diseases. The company's corporate philosophy is rooted in scientific innovation, collaboration, and a patient-centric approach. Celldex Therapeutics Inc strives to develop novel therapies that harness the power of the immune system to target and eliminate cancer cells. With a focus on precision medicine, the company aims to personalize treatment options for patients through targeted therapies and combination approaches. Celldex Therapeutics Inc's dedication to scientific excellence and improving patient outcomes drives their mission to redefine the treatment landscape for cancer and other therapeutic areas.

Celldex Therapeutics Inc is primarily present in the United States.

Celldex Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase 3 clinical trials for RINTEGA®, a targeted immunotherapy for glioblastoma patients, showing promising results. Celldex also made progress in advancing their novel bispecific antibody program, targeting solid tumors and hematologic malignancies. Furthermore, the company entered into strategic collaborations with renowned organizations, including Bristol-Myers Squibb. Celldex's achievements demonstrate their commitment to developing innovative therapies and partnerships that can potentially address critical unmet medical needs in cancer treatment.

Celldex Therapeutics Inc is a renowned biotechnology company specializing in the development of innovative immunotherapies to treat various types of cancer. Established in 1983, Celldex Therapeutics has proven expertise in the field of antibody-based drugs and targeted cancer therapies. The company is dedicated to advancing scientific research and bringing novel treatments to patients in need. With a strong emphasis on clinical trials and strategic collaborations, Celldex Therapeutics has made significant contributions to the oncology community. As a leader in the biotech industry, Celldex Therapeutics Inc continually strives to improve patient outcomes and revolutionize cancer therapeutics.

The main competitors of Celldex Therapeutics Inc in the market include bigger biotechnology companies like Amgen, Inc., Gilead Sciences, Inc., and Novartis AG. These companies also focus on developing innovative therapies and medications for various diseases and medical conditions. Celldex Therapeutics Inc competes with these companies to secure a strong position in the biotechnology industry and gain market share.

Celldex Therapeutics Inc is primarily active in the biopharmaceutical industry.

The business model of Celldex Therapeutics Inc focuses on the development and commercialization of targeted immunotherapies for the treatment of various forms of cancer. Celldex utilizes its expertise in antibody-based therapeutics and vaccines to design and develop innovative treatments that harness the body's immune system to fight cancer cells. The company's approach combines monoclonal antibodies, antibody-drug conjugates, immune modulators, and vaccines to deliver personalized therapies that can potentially improve patient outcomes. Celldex Therapeutics Inc aims to address unmet medical needs in oncology by advancing its pipeline of novel therapeutics and establishing strategic partnerships to drive the commercialization of its products.

مُعامل القيمة السوقية إلى الأرباح لـ Celldex Therapeutics هو ؜-١١٫٠١.

مُعامِل القيمة إلى المبيعات Celldex Therapeutics هو ٤٣٩٫٣٩.

نقاط جودة AlleAktien لـ Celldex Therapeutics هي 5/10.

المتوقعة Celldex Therapeutics الإيرادات هي ٤٫١٦ مليون. USD.

صافي الربح المتوقعة Celldex Therapeutics هو ؜-١٦٥٫٩٠ مليون. USD.

Celldex Therapeutics Inc is a biopharmaceutical company that focuses on the development of therapies for the treatment of cancer and other serious immunological diseases. The company has been listed on NASDAQ since 2004 and is headquartered in Hampton, New Jersey. The business model of Celldex Therapeutics is based on the development and commercialization of innovative therapies tailored to the needs of patients with specific types of cancer. The company specializes in the research and development of antibodies, immunotherapeutics, and other novel technologies that utilize the body's immune system to selectively attack and destroy cancer cells. The company is positioned in three business segments: 1. Cancer Therapeutics: Celldex develops immunotherapeutics that stimulate the body's immune system to selectively attack and destroy cancer cells. The key products in this segment are the monoclonal antibody glembatumumab vedotin and the bispecific molecule CDX-014, which is precisely targeted to biomarkers for detection. 2. Infectious Diseases: Celldex has developed a viral vaccine aimed at combating HPV infections that can cause cervical cancer. With the project-based CPM-Interest system, the company also seeks to combat diseases such as Covid19. 3. Solutions Services: Celldex also offers a wide range of solutions and services tailored to the needs of patients, physicians, hospitals, and the pharmaceutical industry. The solutions include targeted collaboration with business partners to obtain their support in drug development and bring their medications to market with high-quality clinical and preclinical data and low risk. Celldex Therapeutics is a company deeply rooted in research and development. The company continuously invests in innovative technologies and strategies to develop new and effective therapies for the treatment of cancer patients and other serious immunological diseases. In doing so, the company relies on close collaboration with partners from the pharmaceutical industry to optimize development pipelines. Overall, the business model of Celldex Therapeutics is characterized by close collaboration with various partners, continuous investment in research and development, and a clear focus on patient needs and cost-effective solutions. The company has established itself as an innovator in cancer research and constantly strives to develop new therapies and technologies to improve the lives of patients.

يوزع Celldex Therapeutics أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Celldex Therapeutics في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـCelldex Therapeutics هو US15117B2025.

رمز WKN لـ Celldex Therapeutics هو A2PEAB.

الرمز المُختصر لـ Celldex Therapeutics هو CLDX.

خلال آخر 12 شهراً، دفعت Celldex Therapeutics توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Celldex Therapeutics خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Celldex Therapeutics هي .

Celldex Therapeutics يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Celldex Therapeutics دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Celldex Therapeutics يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Celldex Therapeutics المُعلن عنها في ٢٧‏/٨‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٧‏/٨‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٧‏/٨‏/٢٠٢٤.

في العام 2023، وزعت Celldex Therapeutics 0 USD كأرباح أسهم.

يتم توزيع أرباح Celldex Therapeutics بالعملة USD.